Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
Author:
Affiliation:
1. Kleijnen Systematic Reviews Ltd, York, UK
2. Institute of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands
Funder
National Institute for Health Research
Publisher
Subject
Health Policy
Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing;Molecular Therapy - Methods & Clinical Development;2023-12
2. Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis;Journal of Cystic Fibrosis;2023-09
3. Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies;PharmacoEconomics;2023-08-18
4. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del;Journal of Cystic Fibrosis;2023-07
5. Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data;PLOS ONE;2023-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3